No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ofloxacin is primarily eliminated by the kidney. In vitro data suggest that ofloxacin weakly inhibits the renal transporter OAT3 and inhibits OCT2. A clinically significant interaction is unlikely as emtricitabine is not transported by OCT2 and tenofovir is primarily excreted by OAT1.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking